Shibahara (69 resultados)

paperback. Condición: Very Good. Connecting readers with great books since 1972! Used books may not include companion materials, and may have some shelf wear or limited writing. We ship orders daily and Customer Service is our top priority.

Softcover. Condición: Fair. Anmerkungen / beschriftet / Stempel; Leichte Gebrauchsspuren.

Condición: Good. 1989. No edition remarks. 147 pages. No dust jacket. This is an ex-Library book. Signed by the author. Blue cloth covered boards with gilt. Flat signed by the author to front free endpaper. Ex library copy with associated labels, inserts, stamps and annotations. Pages remain bright and clean with minimal tanning and foxing. Binding remains firm. Minor pencil inscriptions to half-title page. Boards have light shelf wear with minor corner bumping and crushing to spine ends. All surfaces tanned and sunned, particularly spine. Gilt lettering remains bright and clear. Some additional mild marks and staining.…

Condición: New.

Paperback. Condición: Brand New. 286 pages. 8.50x5.50x0.72 inches. In Stock.

Condición: As New. Unread book in perfect condition.

Paperback. Condición: New. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).…

Condición: New.

Softcover. Condición: As New. Leichte Kratzer / Abnutzungen / Druckstellen. Coursebook for communicative language activities.

Condición: New. In English.

Softcover. Condición: Bon. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Good. Ammareal gives back up to 15% of this item's net price to charity organizations.

Condición: New. 1st edition NO-PA16APR2015-KAP.

Paperback. Condición: Brand New. 75 pages. 8.94x5.98x0.24 inches. In Stock.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: very good. Gently used. May include previous owner's signature or bookplate on the front endpaper, sticker on back and/or remainder mark on text block.

Hardcover. Condición: Very Good. Estado de la sobrecubierta: No Dust Jacket Issued. First Edition. Signed by Sadao Shibahara on front endpaper, with brief inscription. In English. viii, 191pp. Brick red cloth with gilt lettering. This book is the development of Shibahara's thesis for a doctor's degree entitled, "Topological Approach to Thinking Psychology" which was presented to Kyoto University in Japan on 26th of March in 1971. Text is unmarked and clean aside from the author's signature and inscription. Binding is tight, sturdy, and square. Shelfwear is very minor. From a private home collection. Extremely scarce. Ships same or next business day from Dinkytown in Minneapolis, Minnesota. Signed by Author.…

Paperback. Condición: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.

Paperback. Condición: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.

hardcover. Condición: Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority.

Paperback. Condición: Brand New. 148 pages. Japanese language. 11.81x8.27x0.39 inches. In Stock.

Paperback. Condición: new. Paperback. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Tankobon Hardcover. Condición: Brand New. Japanese language. 9.76x9.13x0.55 inches. In Stock.

Kartoniert / Broschiert. Condición: New. Inhaltsverzeichnis1.Structural biology and mechanism of activation of EGFR 2. EGFR-associated oncogenesis 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC 4. EGFR-TKIs as adjuvant or neoadjuvant therapy.

Paperback. Condición: New.

Paperback. Condición: Brand New. 200 pages. Japanese language. 11.81x8.35x0.39 inches. In Stock.

Paperback. Condición: Brand New. 180 pages. Japanese language. 11.65x8.11x0.32 inches. In Stock.

Paperback. Condición: New. First Edition.

Paperback. Condición: Brand New. 200 pages. Japanese language. 11.65x8.19x0.47 inches. In Stock.

Paperback. Condición: New. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).…